Investigation Launched Against AVITA Medical, Inc. (RCEL) for Securities Fraud
ByAinvest
Wednesday, Aug 20, 2025 5:41 pm ET1min read
RCEL--
According to the company's report, contractors assigned by the Centers for Medicare & Medicaid Services (CMS) failed to properly assign prices or adjudicate claims in a timely manner. This led to a six-month backlog of unpaid claims, causing uncertainty among providers regarding payment expectations and timelines. As a result, the utilization of Recell procedures declined during the first half of the year.
The revelation of this backlog had a significant impact on AVITA's stock price. On August 8, 2025, the stock fell by $1.13, or 21%, to close at $4.25 per share. This drop in stock value has injured investors, prompting the Law Offices of Frank R. Cruz to urge those who lost money to contact them for potentially pursuing a claim to recover their losses.
Investors who purchased AVITA securities and have information relevant to these claims are encouraged to contact the Law Offices of Frank R. Cruz at 310-914-5007, via email at info@frankcruzlaw.com, or visit their website at www.frankcruzlaw.com. For updates, follow them on Twitter at twitter.com/FRC_LAW.
References:
[1] https://www.businesswire.com/news/home/20250820660176/en/Securities-Fraud-Investigation-Into-AVITA-Medical-Inc.-RCEL-Announced-Investors-Who-Lost-Money-Urged-To-Contact-The-Law-Offices-of-Frank-R.-Cruz
[2] https://340breport.com/federal-judge-rejects-health-systems-bid-for-interest-on-340b-medicare-lump-sum-repayments/
AVITA Medical, Inc. (RCEL) is under investigation for possible securities fraud following the release of its Q2 2025 financial results, which revealed a backlog of unpaid provider claims for its wound care product, Recell. As a result, the company's stock price fell 21%. Investors who lost money are urged to contact the Law Offices of Frank R. Cruz for potentially pursuing a claim to recover their loss.
AVITA Medical, Inc. (RCEL), a company specializing in wound care products, is under investigation for possible securities fraud. The Law Offices of Frank R. Cruz announced the probe on behalf of investors who may have been affected by the company's financial reporting. The investigation stems from the release of AVITA's Q2 2025 financial results, which disclosed a significant backlog of unpaid provider claims for its Recell wound care product.According to the company's report, contractors assigned by the Centers for Medicare & Medicaid Services (CMS) failed to properly assign prices or adjudicate claims in a timely manner. This led to a six-month backlog of unpaid claims, causing uncertainty among providers regarding payment expectations and timelines. As a result, the utilization of Recell procedures declined during the first half of the year.
The revelation of this backlog had a significant impact on AVITA's stock price. On August 8, 2025, the stock fell by $1.13, or 21%, to close at $4.25 per share. This drop in stock value has injured investors, prompting the Law Offices of Frank R. Cruz to urge those who lost money to contact them for potentially pursuing a claim to recover their losses.
Investors who purchased AVITA securities and have information relevant to these claims are encouraged to contact the Law Offices of Frank R. Cruz at 310-914-5007, via email at info@frankcruzlaw.com, or visit their website at www.frankcruzlaw.com. For updates, follow them on Twitter at twitter.com/FRC_LAW.
References:
[1] https://www.businesswire.com/news/home/20250820660176/en/Securities-Fraud-Investigation-Into-AVITA-Medical-Inc.-RCEL-Announced-Investors-Who-Lost-Money-Urged-To-Contact-The-Law-Offices-of-Frank-R.-Cruz
[2] https://340breport.com/federal-judge-rejects-health-systems-bid-for-interest-on-340b-medicare-lump-sum-repayments/

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet